HUMANWELL PURACAP is a generic drug manufacturer focused on Neurology, Metabolic.
HUMANWELL PURACAP's Key Drugs
HUMANWELL PURACAP's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
HUMANWELL PURACAP's Recent FDA Approvals
New NDA/BLA approvals for HUMANWELL PURACAP over the last two years — novel drugs only, excluding generics and label supplements.
HUMANWELL PURACAP's Therapeutic Areas
HUMANWELL PURACAP's approved drugs and pipeline span 2 therapeutic areas, led by Neurology and Metabolic. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HUMANWELL PURACAP's Top Competitors
HUMANWELL PURACAP's closest competitors by therapeutic-area and drug-target overlap include Eli Lilly, Roche, and SPECGX LLC. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HUMANWELL PURACAP Pipeline Snapshot
Active clinical trials for HUMANWELL PURACAP across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2016-06-21
- Latest
- 2026-02-27
- Applications
- 6